University of Alabama at Birmingham-ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2023

  1. Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout

    Arthritis and Rheumatology, Vol. 75, Núm. 5, pp. 816-825

2022

  1. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

2021

  1. Flare rate thresholds for patient assessment of disease activity states in Gout

    Journal of Rheumatology, Vol. 48, Núm. 2, pp. 293-298

  2. Which factors predict discordance between a patient and physician on a gout flare?

    Rheumatology (United Kingdom), Vol. 60, Núm. 2, pp. 773-779

2019

  1. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

  2. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout

    Arthritis Care and Research, Vol. 71, Núm. 3, pp. 427-434

2018

  1. Brief Report: Validation of a Definition of Flare in Patients With Established Gout

    Arthritis and Rheumatology, Vol. 70, Núm. 3, pp. 462-467

2017

  1. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210

  2. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150

  3. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015

    The Lancet, Vol. 390, Núm. 10091, pp. 231-266

  4. Treat-To-Target (T2T) recommendations for gout

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 4, pp. 632-638

  5. Weight loss for overweight and obese individuals with gout: A systematic review of longitudinal studies

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 11, pp. 1870-1882

2016

  1. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises

    Arthritis Care and Research, Vol. 68, Núm. 5, pp. 667-672

2015

  1. 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

    Arthritis and Rheumatology, Vol. 67, Núm. 10, pp. 2557-2568

  2. 2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1789-1798

  3. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 385, Núm. 9963, pp. 117-171

  4. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 10010, pp. 2287-2323

  5. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition

    The Lancet, Vol. 386, Núm. 10009, pp. 2145-2191

  6. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013

    The Lancet, Vol. 386, Núm. 9995, pp. 743-800

  7. Imaging as an outcome measure in gout studies: Report from the OMERACT gout working group

    Journal of Rheumatology, Vol. 42, Núm. 12, pp. 2460-2464